Effectiveness Of Drotaverine In Reducing First Stage Labour Duration: A Randomized Controlled Trial

Background: The acceleration of labor is an important issue in obstetrics to ensure the safety and timely outcome of pregnancy. Drotaverine is a drug with known smooth muscle relaxation properties that has been investigated for the possibility of decreasing the first stage labor time. The main purpose of the study was to compare result in labor process of patients receiving drotaverine and those of the control group. Methods: Randomized controlled trial was conducted in Gynae & Obst Department, GMC Teaching Hospital, Gujranwala, a period of 6 months. 248 patients were divided into 2 groups through non-probability consecutive sampling. Data was collected such as patient demographics, gestational age, and duration of labour. SPSS 11 version was utilized for the analysis purpose with the descriptive statistics analysis and t-tests for hypothesis testing. Results: The Mean for the duration of the stage of labour in the drotaverine group was considerably lower with 2.08±0.82 hours compared to 3.10±0.86 hour’s times in controlled group. Stratification analysis by age demonstrated similar results. Mean duration of the active stage of labour was significantly less in the drotaverine group in comparison with control group in all age groups. Conclusion: The results of the current research indicate that drotaverine is a drug that substantially mitigates the duration of labour in women at the first stage. If the investigational drug is put into practice, few instances of risks associated with prolonged labour occur, while the chances of natural labour increase. Specifically, there is lower maternal morbidly, fewer unnecessary caesarean sections, and more normal vaginal deliveries.